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Abstract
Background: Protection against disease or colonization from serotypes related to those in pneumococcal conjugate
vaccines (i.e. cross-protection) vary by serotype; the basis for this variation is not understood. The 13-valent pneumococcal
conjugate vaccine (PCV13) replaced 7-valent conjugate (PCV7) in the USA in 2010 allowing assessment of PCV7 and PCV13
immunogenicity and functional cross-protection in vitro.
Methods: Post-primary, pre-booster and post-booster sera from American Indian children receiving exclusively PCV7 or
PCV13 were collected. IgG was measured by ELISA for 13 vaccine serotypes; functional antibody was assessed by
opsonophagocytic killing assays for serotypes 6A/B/C and 19A/F.
Results: Post-primary IgG geometric mean concentrations (GMC) for serotypes 4 and 9V were lower in PCV13 recipients
while 19F GMCs were higher. Only 19F differences persisted after receipt of the booster dose. Functional antibody activity
was higher among PCV13 recipients for 6A, 6C, 19A and 19F (p,0.04), and among PCV7 recipients for 6B (p = 0.01).
Following PCV7, functional antibodies to 6A but not 19A were observed. High levels of 6C functional activity were seen after
PCV13 but not PCV7.
Conclusions: Functional antibody activity against 6A/B/C and 19A/F suggest that PCV13 is likely to control the 19A disease
and 6C disease remaining despite widespread use of PCV7.
Citation: Grant LR, O’Brien SE, Burbidge P, Haston M, Zancolli M, et al. (2013) Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines
and the Development of Functional Antibodies to Cross-Reactive Serotypes. PLoS ONE 8(9): e74906. doi:10.1371/journal.pone.0074906
Editor: Ray Borrow, Health Protection Agency, United Kingdom
Received April 11, 2013; Accepted August 7, 2013; Published September 23, 2013
Copyright:  2013 Grant et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project described was supported by Award Number R01MD004011 from the National Center on Minority Health and Health Disparities. The
content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center on Minority Health and Health
Disparities or the National Institutes of Health. This work was also funded by Pfizer, Inc. (Grant number: 6096A1-4013). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: KOB, LRG, RCW and RR have research grant support from GlaxoSmithKline (GSK). KOB has received honoraria for participation in external
expert advisory committees on pneumococcal vaccines convened by Merck, Sanofi-Pasteur, and GSK. MS has research grant support from GSK and has received
honoraria for participation in external expert advisory committees on pneumococcal vaccines convened by GSK. DG has received honoraria for participation in
external expert advisory committees on pneumococcal vaccines convened by Pfizer, GSK and Merck. DG’s laboratory performs contract research for Merck and
GSK. No other authors report a conflict of interest. This does not alter the authors’ adherence to all of the PLOS ONE policies on sharing data and materials.
* E-mail: klobrien@jhsph.edu
Background
The seven-valent pneumococcal conjugate vaccine (PCV7,
Prevnar, Pfizer) was licensed and introduced in 2000 into the
United States (US) infant immunization schedule; doses are
administered at 2, 4, 6 and 12–15 months of age. The incidence of
invasive pneumococcal disease (IPD) from the vaccine serotypes (4,
6B, 9V, 14, 18C, 19F and 23F) fell rapidly following PCV7
introduction, although serotype-specific efficacy varied by serotype
(87% (19F) to 100% (9V)) [1]. For non-invasive disease, serotype
specific efficacies have shown even greater variation; in a PCV7
efficacy trial of acute otitis media (AOM) efficacy ranged from only
37% for serotype 19F to 79% for serotype 6B [2]. This variability
in efficacy was not associated with significant differences in
absolute antibody concentrations but was linked to increased
antibody requirement for killing of 19F, possibly explained by the
thickness of the 19F capsule and increased resistance to C3
deposition [3].
In addition to serotype specific efficacy, there has been interest
in cross-protective immunity induced by the constituents of PCV7
to closely related serotypes. Prior to the widespread use of PCV7, it
was unclear whether 6B and 19F induced antibodies would impact
6A and 19A carriage and disease respectively. Following
implementation, here too variation has been seen. Use of PCV7
has resulted in 76% effectiveness against 6A IPD, with no impact
on 6C disease [4], and an estimated 26% effectiveness against IPD
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caused by 19A [1]. So, unlike the ability of 6B-induced antibodies
to cross-protect against 6A disease, antibodies inducted by 19F
antigen present in PCV7 have provided limited cross-reactive
protection against 19A disease [5]. To go beyond the disease
protection capacity of PCV7, extended valency vaccines have been
developed which include some or all of six additional capsular
polysaccharides (1, 3, 5, 6A, 7F and 19A). One of these vaccines,
designated PCV13 (Prevnar-13, Pfizer), is licensed in the US and
replaced PCV7 in the first quarter of 2010 for routine use; it and
the 10-valent product (PCV10, GlaxoSmithKline) are used in
many countries around the world. The US implementation of
PCV13 provides the opportunity to more deeply investigate the
cross-reactive potential of the serogroup 6 and 19 antigens
included in the vaccine and thus anticipate the likely impact this
vaccine will have on disease, especially in populations with a high
disease burden.
American Indians living on or around the Navajo and White
Mountain Apache reservations in the Southwest US have
increased rates of pneumococcal nasopharyngeal (NP) colonization
and disease compared to the general US population [6,7].
However, PCV7 has had a profound impact on reducing IPD
due to vaccine serotypes to negligible levels [8,9]. The presence of
cross protection to 6A by the 6B conjugate that is contained in
PCV7 has been apparent. During the PCV7 routine use era,
population-based active surveillance among Navajo and White
Mountain Apache communities demonstrated that serotype 6A
IPD rates decreased compared to pre-PCV7 use era (2006–2008
vs. 1998–2000) although NP colonization and IPD rates caused by
serotype 6C increased [4]. Invasive disease from 19A has also
increased over time among US children (including the Navajo and
White Mountain Apache) and emerged as the leading serotype
causing IPD in other US populations [8,10]. As expected based on
trends in 19A IPD, 19A also became a frequent cause of NP
colonization; from 2006–2008, 19A was among the five most
frequent serotypes isolated from Navajo and White Mountain
Apaches enrolled into a longitudinal, household-based study of
pneumococcal colonization [11]. Interestingly, vaccine-type 19F,
unlike other PCV7 serotypes, continues to circulate as a colonizing
serotype and is occasionally detected as a cause of IPD among the
Navajo and White Mountain Apaches.
In March and April 2010, PCV13 replaced PCV7 among
Navajo and White Mountain Apache infants thereby providing an
opportunity to evaluate the comparative immunogenicity of PCV7
and PCV13. Of particular interest was the ability of sera taken
following administration of PCV7 or PCV13 to kill serotypes 6B
and 19F and related serotypes 6A, 6C and 19A as this would
provide information on the likely degree of direct and cross-
protection afforded by PCV13 in this high risk population.
Methods
IRB Approval & Consent
The Institutional Review Boards of the Johns Hopkins
Bloomberg School of Public Health and the Navajo Nation
approved this study. Tribal approval was obtained from the
Navajo Nation. Parents and guardians signed a written informed
consent document for each child participant.
Study Design
An observational immunogenicity study of PCV7 and PCV13
was nested within a community-based study of pneumococcal NP
colonization conducted from January 2010 to March 2012
enrolling American Indian children and their families who lived
on or near Navajo Nation. The population of Navajo Nation is
more than 250,000 people who live on 27,000 square miles of land
that is divided into nine service units as defined by the Indian
Health Service (IHS). From the service units of Chinle, Fort
Defiance, Gallup and Shiprock, families and their infants 7–24
months of age were recruited at the primary IHS health facility on
each service unit for enrolment into the colonization study. Infants
who received three doses of PCV7 or three doses of PCV13 as part
of the routine immunization program were eligible for the nested
immunogenicity study, which was determined by review of the
infant’s medical record. Following consent by the parent or
guardian, blood was collected after primary immunization, prior
to and/or following the booster dose. The goal was to collect 600
bloods total: 100 bloods at each of the three time points from the
same or assorted patients who received either PCV7 (300
specimens) or PCV13 (300 specimens). Therefore, children could
contribute to any or all of the sampling time points depending on
their immunization status.
The ideal blood collection criteria are: (1) at least 28 days and
no more than 112 days had to separate the primary series doses
and (2) the booster dose had to occur at least 120 days after
completion of the primary series. Post-primary and post-booster
blood draws had to be completed within 98 days after the last dose
of the primary series and within the first year of life or after the
booster dose and before 20 months of age. Pre-booster blood was
drawn anytime in the 14-day window prior to the booster dose.
There were no additional exclusion criteria for a specimen to be in
the analysis.
Laboratory Procedures
Approximately 4 mL of blood collected by venipuncture,
separated and serum stored at 280uC. Serum was assayed for
antibodies to 13 vaccine-type capsular polysaccharides (1, 3, 4, 5,
6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) at the University
College London, Institute of Child Health, a World Health
Organization (WHO) reference laboratory for pneumococcal
serology. Sera were assayed using the WHO reference enzyme-
linked immunosorbent assay (ELISA) following adsorption with
cell wall polysaccharide and 22F polysaccharide at a concentration
of 10 mg/mL as previously described [12], and in detail at http://
www.vaccine.uab.edu/ELISA%20Protocol.pdf. To evaluate func-
tional antibody to serotypes 6A, 6B, 6C, 19A and 19F, a subset of
post-primary sera from PCV7 and PCV13 recipients were
selected, matching for anti-19F or anti-6B concentrations. Sera
were analyzed by a multiplexed opsonophagocytic assay (OPA,
titer $1:8 considered positive) [13]. To assess the contribution of
type specific antibody to killing of cross-reactive antigens, sera
were retested by OPA after adsorbing sera with purified 19F, 19A,
6A, 6B or 6C capsular polysaccharide (ATCC for 19F and 19A
and Statens Serum Institute for 6A, 6B, and 6C) one at a time and
reported as the titer where 50% of bacteria were killed.
Statistical Analyses
Serotype-specific ELISA geometric mean concentrations
(GMCs) were calculated for each blood draw and comparisons
made between those who received PCV7 or PCV13. Serotype-
specific IgG values were log-transformed and used in Generalized
Linear Models with log(IgG) values following a Gaussian
distribution to adjust for differences by vaccine group in the
number of days between the last dose that occurred immediately
prior to the blood draw. A robust variance estimator was used in
the model to account for dependent observations when a child
contributed more than one specimen across collection times. The
adjusted IgG values from the models were then used to calculate
the GMC and corresponding 95% confidence intervals. The
Pneumococcal Cross-Reactive Antibody
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coefficient in the model for vaccine group represented the
difference in the adjusted GMCs between the vaccine groups.
The model tested inclusion of an interaction term between vaccine
group and time between dose and the blood draw to account for
differences in antibody concentration between vaccine groups.
The immune response to the booster dose was measured by
comparing the pre- and post-booster GMCs for each serotype by
vaccine. A p-value ,0.05 was considered statistically significant.
We calculated the proportion of participants who achieved the
threshold antibody concentration used in evaluation of vaccines
against type-specific IPD; we used 0.35 mg/mL (the value from the
combined results of the American Indian, Northern California and
South African PCV7 efficacy trials [14]) and 1.0 mg/mL (the value
derived from the American Indian trial alone [15]).
Serum samples from PCV7 or PCV13 recipients were matched
on 6B and 19F ELISA concentrations, resulting in a subset of post-
primary sera that were tested by OPA for functional antibody to
serotypes 6A, 6B, 6C, 19A and 19F. Sera were matched using five
IgG concentration (mg/mL) categories of low (,0.5), medium-low
(0.5–0.99), medium (1.00–4.00), medium-high (4.01–10) and high
(.10.00). Geometric mean titers (GMTs) were calculated and
compared. Correlation between the OPA GMTs and ELISA
GMCs was evaluated by a Pearson correlation coefficient (r). The
percentage of functional antibody adsorbed by free capsular
polysaccharide was compared between the PCV7 and PCV13
vaccine recipients using Fisher’s exact test. GMTs were compared
between vaccine groups on the log scale for individual serotypes by
a paired two-sample t-test for data following a normal distribution.
The non-parametric Wilcoxon signed-rank test was used to
compare GMTs that were not normally distributed on the log-
scale. Analyses were completed using STATA (version 11; College
Station, TX). Data are available from the authors upon request.
Results
In total 561 sera were collected (159 post-primary, 222 pre-
booster, 180 post-booster) between April 2010 and October 2011.
Of the 561 collected sera, 209 children contributed one specimen,
Table 1. Dosing and draw time characteristics of study participants contributing to immunogenicity analysis.
Post-Primary Series Pre-Booster Dose Post-Booster Dose
Characteristics
PCV7
(n =32)
PCV13
(n =85) p-valuea
PCV7
(n =68)
PCV13
(n =89) p-value
PCV7
(n=33)
PCV13
(n=100) p-value
No. Female (%) 14 (44) 40 (47) 0.75 33 (49) 39 (44) 0.56 18 (55) 44 (44) 0.29
Mean age in days at dose (min, max)
Dose 1 74.9 57.9 0.004 63.8 59.9 0.21 55.8 63.4 0.07
(42, 211) (42, 122) (42, 165) (30, 127) (41, 82) (41, 193)
Dose 2 149.9 136.1 0.008 133.0 131.6 0.56 132 134.5 (111, 0.52
(110, 259) (120, 185) (107, 248) (111, 174) (115, 178) 278)
Dose 3 217.5 202.8 0.01 198.7 197.2 0.60 199.3 199.3 0.99
(181, 314) (182, 259) (174, 306) (171, 248) (181, 237) (365, 555)
Dose 4 – – – 391.8 377.4 0.002 393.2 379.1 0.02
(366, 560) (365, 445) (366, 574) (365, 555)
Mean days between doses (min, max)
Doses 1 and 2 74.9 78.2 0.40 69.2 71.6 0.41 76.2 71.1 0.12
(28, 111) (32, 107) (29, 104) (35, 110) (41, 111) (41, 111)
Doses 2 and 3 67.6 66.7 0.82 65.7 65.6 0.98 67.3 64.8 0.42
(37, 106) (28, 110) (29, 106) (29, 100) (30, 106) (28, 100)
Doses 3 and 4 188.9 188.2 0.95 193.1 180.2 0.006 193.9 179.8 0.008
(100, 365) (129, 341) (137, 379) (124, 257) (138, 354) (140, 257)
Days between last
dose and blood draw
50.5 39.1 0.003 192.1 179.9 0.009 48.8 28.3 ,0.0001
(15, 94) (15, 83) (137, 379) (124, 257) (19, 83) (7, 98)
aProportions compared by Fisher’s exact test.
doi:10.1371/journal.pone.0074906.t001
Figure 1. Concentrations of serotype-specific IgG from sera
collected post-primary from PCV7 and PCV13 recipients.
doi:10.1371/journal.pone.0074906.g001
Pneumococcal Cross-Reactive Antibody
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e74906
73 children provided two specimens (N=146) and 17 children
gave three specimens (N= 51). Table 1 provides comparisons of
sera obtained from PCV7 and PCV13 recipients that contributed
to the immunogenicity analysis. Sera that were not included in
analyses failed to meet criteria related to intervals of time between
vaccine doses, time between dose and blood draw, number of
vaccine doses before the blood draw, mixed use of PCV7 and
PCV13 and the age at blood draw (Figure S1). There were 117
post-primary, 157 pre-booster and 133 post-booster (total = 407)
sera that met the inclusion criteria for analysis. Children who
received three PCV13 primary doses were younger at each dose
than PCV7 recipients (p,0.01), PCV13 children had shorter
intervals of time separating some doses (p,0.008) and fewer days
between the previous dose and the blood draw compared to PCV7
children (p,0.009; Table 1).
Comparison of PCV7 and PCV13 Immunogenicity
Post-primary GMCs for the seven serotypes common between
PCV7 and PCV13 (hereafter referred to as ‘‘common serotypes’’)
were significantly lower for serotypes 4 (p = 0.008) and 9V
(p= 0.001) and higher for serotype 19F (p= 0.02) among PCV13
participants compared with PCV7 participants after adjusting for
differences in the timing of blood collection (Figure 1). Post-
primary GMCs for the additional 6 serotypes in PCV13 were
significantly higher in the PCV13 group (p#0.001; Figure 1). Pre-
boost antibody levels were lower than post-primary levels for both
vaccine groups but all rose sharply following the booster dose
irrespective of vaccine type. Among the seven common serotypes,
the GMCs following the booster dose were similar between
vaccine groups for six serotypes after adjusting for the time
between the booster dose and the blood draw (p.0.3); however,
post boost GMCs for 19F and the additional 6 serotypes in PCV13
were higher for PCV13 recipients (p#0.001; Figure 2).
For the common serotypes at least 93% of children who
received PCV7 or PCV13 had post-primary and post-boost
serotype-specific IgG that reached the threshold used by licensing
agencies as a vaccine efficacy correlate (i.e. $0.35 mg/mL)
(Table 2). When assessing cross reactive serotypes for PCV7
recipients at least 68% achieved IgG $0.35 mg/mL for 6A and
19A following primary immunization, which was significantly
lower than the PCV13 recipients, but was present in a substantial
proportion of PCV7 vaccinated children. Over 78% of PCV7 and
63% of PCV13 recipients had post-primary serotype-specific IgG
concentrations $1.0 mg/mL for the common serotypes after
completing the primary series. A larger percentage of PCV13
children achieved serotype 19F IgG concentrations greater than or
equivalent to each of the thresholds after the booster dose
compared to PCV7 recipients (p,0.01).
Comparison of Functional Antibody Elicited by PCV7 and
PCV13
Functional antibody activity (OPA) against 19A and 19F was
also assessed in a subset of post-primary sera among PCV7 and
PCV13 recipients (Table 3). Serotype 19F OPA titers had a
positive correlation with anti-19F IgG ELISA concentrations for
both PCV7 (r = 0.67) and PCV13 (r = 0.87). Despite matching for
19F IgG concentration, PCV13 recipients had higher 19F
(p = 0.04) opsonic titers compared to PCV7 recipients indicating
that 19F antibodies induced by PCV13 are more highly functional
than PCV7 induced antibodies. By contrast with serotype 19F,
19A OPA titers and anti-19A IgG were positively correlated
(r = 0.49) only among PCV13 recipients. None of the PCV7
recipients demonstrated functional 19A antibody activity
(GMT=8.0).
To determine the source of 19F functional antibody activity,
sera were adsorbed with 19A polysaccharide and re-tested for 19F
functional activity; there were similar reductions in anti-19F
activity for PCV7 (29%) and PCV13 (32%; p= 0.84) recipients
(Table 3). Having shown that the PCV7 recipients have 19A
antibodies but that they are not functional, this finding of
equivalent reduction in 19F functional activity was unexpected.
When the sera were likewise adsorbed with 19F polysaccharide
Figure 2. Concentrations of serotype-specific IgG from sera collected post-booster from PCV7 and PCV13 recipients.
doi:10.1371/journal.pone.0074906.g002
Pneumococcal Cross-Reactive Antibody
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and re-tested for 19A functional activity, the PCV13 recipients
had a 40% reduction in functional activity (the PCV7 recipients
had no 19A functional activity even before adsorption) and as
expected almost complete inhibition of 19F activity among both
the PCV7 and PCV13 recipients.
Turning to serogroup 6, functional serotype 6B responses (OPA
titers) were assessed and evaluated for correlation with 6B IgG
concentrations; they were highly correlated for PCV13 recipients
(r = 0.89) but unexpectedly lacked any linear correlation for sera
from PCV7 recipients (r = 0.08). There was no linear correlation
between anti-6A IgG concentrations and 6A OPA titers for either
PCV7 or PCV13 recipients (r =20.11 [PCV7]; r = 0.08
[PCV13]). Despite matching on 6B IgG concentrations, PCV7
recipients had higher functional geometric mean 6B antibody
titers compared to PCV13 (5558 versus 3221; p= 0.01; Table 4).
Serotype 6A and 6C functional antibody titers were higher for
PCV13 than PCV7 recipients (6A: 3042 versus 1524, p = 0.01; 6C:
2003 versus 381, p= 0.004; Table 4).
The reduction in functional antibody activity following adsorp-
tion of sera with 6A, 6B or 6C polysaccharide is shown in Table 4.
Homologous polysaccharide adsorption (e.g. 6A adsorption prior
to 6A OPA testing) fully eliminated functional activity, as expected
and demonstrated the specificity of the antibodies. Adsorption by
heterologous polysaccharide had variable effect on OPA activity
depending on the vaccine administered and the serotype tested.
Notably, serotype 6B adsorption resulted in full reduction in 6A
and 6C OPA activity for PCV7 but not PCV13 immunized
children. Furthermore, 6A and 6C adsorption resulted in only
partial reduction in OPA for 6B among both PCV7 and PCV13
immunized children.
Discussion
With the replacement of PCV7 by PCV13 in national
immunization programs it is critical that data on the likely efficacy
of PCV13, particularly in high-risk populations, is rapidly gathered
as PCV13 was licensed on immunogenicity alone. This study is the
first to assess PCV13 immunogenicity as well as functional
antibody activity in a population at high risk for IPD and also
the first study to evaluate in detail immunologic cross protection in
children when vaccine is administered according to the US
national immunization schedule of 2, 4, 6 and 12 months of age.
Although PCV13 recipients were younger at each primary dose
than those who received PCV7 (p#0.01), the IgG response to
Table 2. Percentage of participants who received PCV7 or PCV13 and achieved pneumococcal IgG antibody concentrations
$0.35 mg/mL or $1.0 mg/mL.
Post primary Pre-Booster Post-Booster
Serotype
Threshold,
mg/mL
PCV7%
(n=32)
PCV13%
(n=85) p-valuea
PCV7%
(n=68)
PCV13%
(n=89) p-value
PCV7%
(n=33)
PCV13%
(n=100) p-value
4 $0.35 100.0 96.5 0.28 47.1 43.8 0.78 100 99.0 0.56
$1 84.4 78.8 0.54 4.4 6.7 0.89 84.8 87.9 0.68
6B $0.35 96.9 97.6 0.82 77.9 80.9 0.68 96.9 100 0.08
$1 90.6 85.7 0.50 25.0 25.8 0.95 93.8 98.0 0.24
9V $0.35 100.0 96.4 0.28 52.9 39.3 0.25 93.8 100 0.01
$1 81.3 63.1 0.10 5.9 4.5 0.93 78.1 86.9 0.28
14 $0.35 100.0 97.6 0.38 97.1 93.3 0.29 100 99.0 0.57
$1 96.9 97.6 0.82 76.5 83.1 0.35 100 99.0 0.57
18C $0.35 100.0 96.4 0.28 29.4 30.3 0.95 96.9 98.0 0.72
$1 78.1 71.4 0.52 0 4.5 – 78.1 83.8 0.51
19F $0.35 100.0 100 – 65.7 87.6 0.00 93.8 100 0.01
$1 90.6 95.2 0.37 23.9 42.7 0.02 90.6 99.0 0.02
23F $0.35 100.0 96.4 0.28 67.6 48.9 0.07 100 99.0 0.57
$1 87.5 80.7 0.43 20.6 14.8 0.69 93.8 97.0 0.42
6A $0.35 68.8 97.6 ,0.0001 45.6 91.0 ,0.0001 87.5 100 0.0004
$1 34.4 96.4 ,0.0001 13.2 52.8 0.03 62.5 99.0 ,0.0001
19A $0.35 75.0 98.8 ,0.0001 70.8 89.8 0.01 82.8 100 ,0.0001
$1 31.3 90.5 ,0.0001 27.7 37.5 0.48 58.6 99.0 ,0.0001
1 $0.35 0 98.8 – 3.3 76.4 0.02 0 100 –
$1 0 90.4 – 0 19.1 – 0 91.9 –
3 $0.35 22.2 96.4 ,0.0001 21.8 55.0 0.04 20.0 97.9 ,0.0001
$1 16.7 63.9 0.10 5.5 12.5 0.73 10.0 73.4 0.02
5 $0.35 16.1 97.6 ,0.0001 14.9 53.9 0.02 34.4 96.0 ,0.0001
$1 0 59.5 – 0 10.1 – 9.4 73.7 0.43
7F $0.35 10.3 100.0 ,0.0001 9.1 91.0 ,0.0001 3.0 100 –
$1 0 98.8 – 0 46.1 – 0 99.0 –
aProportions compared by Fisher’s exact test.
doi:10.1371/journal.pone.0074906.t002
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vaccine was comparable for common serotypes 6B, 14, 18C and
23F and significantly higher for 19F, another serotype common to
both products. Greater than 95% of PCV13 recipients met or
exceeded the correlate of vaccine efficacy used for licensure
($0.35 mg/mL) for all serotypes, a proportion similar to that of the
older PCV7 recipients for the serotypes common to both products,
Furthermore, OPA results of post-primary sera demonstrated that
age at receipt of the PCV13 primary series did not affect
generation of functional antibody.
The time between the third primary dose or booster dose and
the subsequent blood draw was shorter for PCV13 recipients
compared to those who received PCV7 (p,0.009). As waning of
antibody concentrations would be less between the last dose and
blood draw for PCV13 recipients, we adjusted for these differences
in the immunogenicity analysis. After adjustment, the GMCs for
serotypes 4 and 9V were higher following PCV7 while 19F was
higher after PCV13. However, the proportion of recipients with
GMCs above the vaccine evaluation threshold was similar for all
common serotypes. Therefore, these differences in GMCs are not
considered to be biologically relevant.
Following receipt of the booster dose, IgG concentrations to six
of the seven common serotypes were similar, which agrees with
comparative data previously published for both US and German
children [16,17]. Serotype 19F IgG levels were however superior
in our study for the PCV13 recipients at all time points. This might
be accounted for by the contribution of cross-reactive 19A
antibodies induced by PCV13 but has not been described before.
This observation is supported in our study by the higher 19F OPA
titers in PCV13 recipients when matched on 19F IgG concentra-
tions and suggests that PCV13 may confer enhanced protection
from 19F disease over and above that seen in the PCV7 era.
Encouragingly, our results also show that for the seven common
serotypes in both vaccines, IgG concentrations were similar
compared to previous studies among various populations that
have been studied including the same population of American
Indian children [18], other children in the United States [19,20]
and other developed [21,22] and developing countries [23,24].
The antibody response to the six additional serotypes in PCV13
was superior for PCV13 versus PCV7 at all time points as
expected. A significant percentage of PCV7 recipients achieved
antibody concentrations for vaccine-associated serotypes 6A and
19A above $0.35 mg/mL, presumably through induction of anti-
6A and anti-19A IgG by the 6B and 19F conjugate antigens or by
natural exposure (for 19A only since there is virtually no 6A
colonization in the community). However, the absence of 19A
opsonophagocytic activity in PCV7 recipients indicates that these
antibodies are not functional against 19A and explains why that
disease has continued to rise despite widespread PCV7 immuni-
zation in the USA and elsewhere [25–30]. Interestingly, adsorp-
tion of PCV7 induced sera with purified 19A polysaccharide
reduced 19F functional activity, revealing that those same 19A
binding antibodies induced by 19F antigen in PCV7 vaccine are
functional to some degree against 19F. It is possible that low levels
of cross-reacting IgG detected in this way are not sufficient to
bring about killing of 19A and higher concentrations, as has been
described for 19F, are required [3]. This merits further
exploration.
In contrast with 19A, the finding of functional cross-reacting 6A
antibodies following PCV7 vaccination is not unexpected as it
correlates with clinical observations of near elimination of type 6A
disease and colonization following widespread PCV7 use [31].
Detection of functional serotype 6C activity in the PCV7
recipients is surprising given that there has been little impact on
6C colonization or disease following PCV7 use [4,32,11] and that
immunochemically 6B induced antibodies are not predicted to
bind 6C [33]. This 6C cross-reacting phenomenon following
PCV7 or PCV13 has been described before [31,34]. However, in
our study 6C functional titers following PCV7 were significantly
lower than those seen following PCV13. Following PCV13, both
6B and 6A induced antibodies combine to cross react with 6C,
which is reflected in the fact that 6B adsorption completely
Table 3. Inhibition of serotype-specific 19A or 19F opsonophagocytic activity (GMTs) by purified polysaccharide following PCV7 or
PCV13 immunization.
OPA Results following adsorption with purified polysaccharide
Serotype
OPA Results Without
Adsorption Serotype 19A polysaccharide adsorption Serotype 19F polysaccharide adsorption
GMT GMT % inhibition p-valueb GMT % inhibition p-value
(95% CI) p-valuea (95% CI) p-value (95% CI) p-value
19A – N= 18 pairs
PCV7 4.0 0.0002 4.0 0.0002 0 ,0.0001 4.0 0.0002 0 0.003
(4.0–4.0) (4.0–4.0) (4.0–4.0)
PCV13 293.3 25.9 91.1 177.0 39.6
(139.9–614.7) (18.5–36.5) (88.6–353.6)
19F – N= 19 pairs
PCV7 237.9 0.04 168.2 0.05 29.3 0.84 25.9 0.004 89.1 0.61
(100.8–561.4) (75.9–372.3) (17.8–33.2)
PCV13 547.3 370.8 32.2 34.3 93.7
(328.3–912.4) (215.3–638.8) (29.9–39.2)
aGMTs compared by paired t-test or Wilcoxon signed-rank test. In the event that no functional activity was observed, a titer value of 4.0 was assigned as the OPA result.
No functional 19A activity was observed for any samples obtained from PCV7 participants resulting in a GMT of 4.0.
bProportions compared by Fisher’s exact test.
doi:10.1371/journal.pone.0074906.t003
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inhibited PCV7 sera from killing 6C but only reduced killing by
50% in the PCV13 recipients. It is conceivable that these higher
6C functional titers following PCV13 could have an impact on 6C
disease. This is further suggested by colonization studies that
showed reductions in 6C carriage among PCV13 recipients
including in this American Indian population [35,36]. More
complete observations and formal analysis from colonization and
disease surveillance will be coming from a variety of countries in
the near future.
Sera from PCV7 and PCV13 post-primary recipients were
matched on 6B IgG concentrations to minimize the impact of
differences in 6B IgG concentration on comparisons of functional
antibody activity. In spite of this matching, the functional activity
of serotype 6B antibody was higher for PCV7 recipients compared
to children who received PCV13. Thus, gram-for-gram, PCV7-
induced 6B antibody appear to be more functional than PCV13
induced antibody; similar results were observed by Cooper et al.
[34] comparing PCV7 and PCV13 6B OPA titers. The reason for
this difference is unclear as PCV13 contains slightly more purified
6B polysaccharide (4.4 mg per dose compared to 4.0 mg in a dose
of PCV7), slightly more carrier protein CRM197 (34 mg compared
to 20 mg per dose of PCV7) and identical amounts of aluminium
phosphate (125 mg as aluminium phosphate). Changes in PCV7
and PCV13 manufacturing including conjugation or interference
from the additional serotypes may account for the difference.
Pneumococcal conjugate vaccines have had a significant impact
on reducing IPD and colonization caused by vaccine serotypes in
populations at high risk of IPD such as American Indians.
Functional analyses of the vaccine serotype and cross-reactive
antibodies demonstrate that their function is less specific than
originally understood. Our analyses indicate that PCV13 could
provide enhanced protection against serotypes included in the
vaccine (i.e. 19F) and those not present in the vaccine (i.e. 6C)
compared to that seen with PCV7 although for other serotypes (i.e.
6B) equivalence with PCV7 will need to be monitored. Compar-
isons of IPD and pneumococcal colonization trends before and
after conjugate vaccine introduction can contribute to our
understanding of the population-level impacts of PCV on both
immunized and un-immunized persons. Because there are a
significant number of pneumococcal serotypes that are clinically
relevant, functional analyses such as this one are important tools to
improve understanding the contribution of PCV products to
disease reduction. Furthermore, studies such as this help to focus
attention on potential risks associated with product switches, and
provide the biologic basis for these clinical disease reduction
observations.
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